Sandoz partners with Adalvo to commercialize semaglutide in Brazil after ANVISA approval

Reuters2026/07/29 09:30

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Sandoz secured marketing authorization in Brazil for Owozy (semaglutide) to be commercialized through a partnership with Adalvo.
Deal gives Sandoz commercial rights in an estimated USD 1.8 billion Brazilian GLP-1 market.
Launch targeted for the second half of 2026; product uses a pre-filled multi-dose disposable pen.
Sandoz expects no material 2026 financial contribution from any potential generic semaglutide launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sandoz Group AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2373154_en) on July 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Sandoz partners with Adalvo to commercialize semaglutide in Brazil after ANVISA approval

You may also like

Crypto prices